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Intrasynovial tendon injuries are among the most challenging in orthopedics. Despite significant
improvements in operative and rehabilitation methods, functional outcomes continue to be limited
by adhesions, gap formation, and rupture. Adhesions result from excessive inflammation, whereas
tendon gapping and rupture result from inflammation-induced matrix degradation and insufficient
regeneration. Therefore, this study used a combined treatment approach to modulate inflammation
with adipose-derived mesenchymal stromal cells (ASCs) while stimulating tendon regeneration with
connective tissue growth factor (CTGF). ASCs were applied to the repair surface via cell sheets and
CTGF was delivered to the repair center via porous sutures. The effect of the combined treatment was
assessed fourteen days after repair in a canine flexor tendon injury model. CTGF, either alone or with
ASCs, reduced inflammatory (IL1B and IL6) and matrix degrading (MMP3 and MMP13) gene expression,
while increasing anti-inflammatory gene (IL4) expression and collagen synthesis compared to control
repairs. The combined treatment was more effective than CTGF treatment alone, reducing the
inflammatory IFNG and scar-associated COL3A1 gene expression and increasing CD146+ tendon stem/
progenitor cells at the tendon surface and interior along the core suture tracks. Therefore, the combined
approach is promising in promoting early flexor tendon healing and worthy of further investigation.
Tendon injuries are common, affecting a large portion of the population and leading to physical impairment and
large societal costs1,2. Many of these injuries are open wounds requiring extensive surgery, including complex
mid-substance intra-synovial flexor tendon suturing methods2–4. Despite advances in operative techniques and
rehabilitation methods, the outcomes of tendon repair are highly variable and result in a substantial clinical burden. Transected intrasynovial flexor tendons in the hand are particularly problematic, requiring operative repair
and extensive rehabilitation in order to restore hand function. Although there have been significant improvements
in tendon repair and rehabilitation, functional outcomes continue to be limited by adhesions, gap formation and
rupture2,4,5. Adhesions result from excessive inflammation leading to matrix deposition between the repair surface and the surrounding sheath, whereas tendon gapping and rupture result from inflammation-induced matrix
degradation and insufficient matrix regeneration to withstand applied loads at the repair site6–9.
Biologic therapies have the potential to improve these outcomes. Specifically, in prior studies, we demonstrated that adipose-derived mesenchymal stromal cells (ASCs) modulate tendon responses and facilitate regenerative healing via promotion of macrophage polarization toward the regenerative M2 phenotype and away from
the default inflammatory M1 phenotype10,11. Furthermore, growth factors, such as bone morphogenetic protein
12 (BMP 12) and connective tissue growth factor (CTGF), have been shown to stimulate tendon regeneration
by inducing exogenous and endogenous stem cell tenogenic differentiation12–14. However, due to the limited
availability of effective, safe, and clinically feasible approaches for site-specific delivery of cells and growth factors to tendon, few studies have attempted to concurrently modulate inflammation and stimulate regeneration.
Therefore, we established a biocompatible and tendon-specific system to deliver autologous ASCs to the tendon
repair surface with cell sheets10,11 and growth factors to the interior of the tendon via porous sutures15,16. Using
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Figure 1. Structural, material, and delivery properties of porous sutures. (a) Representative scanning
electromicroscopy image of the surface of a porous suture. (b) Pore size (the length of major axis) distribution
of porous suture. (c) Mechanical properties of porous sutures compared to unmodified sutures. (d) Cumulative
release of CTGF from porous sutures preloaded with 30 µg/mL CTGF.
these innovative approaches, the current study investigated the effects of concurrent and site-specific applications
of ASCs and CTGF on tendon healing using a clinically relevant canine flexor tendon injury and repair model17,18.
It was hypothesized that ASCs and CTGF, by modulating inflammation and promoting matrix synthesis at the
repair site, would enhance healing at 14 days after tendon repair.

Results

Porous sutures retain the mechanical properties of unmodified sutures and can deliver growth
factor in a sustained manner. To deliver CTGF to the interior of repaired tendons, 4-0 Supramid sutures

were modified to create pores in their outer layer15,16. The resulting pores were visualized via scanning electron microscopy (Fig. 1a). Quantitative analysis revealed a mean pore area of 0.75 ± 1.64 µm2 and a mean length
of the pore major axis of 0.98 ± 1.12 µm (Fig. 1b). Porous sutures exhibited mechanical properties comparable
to unmodified sutures (Fig. 1c). To examine the capacity of the porous suture to deliver growth factor, CTGF
(30 µg/mL) was loaded into porous sutures via a heparin/fibrin delivery system19,20. The release kinetics of CTGF
from the loaded sutures was determined in vitro in three independent loading experiments. After an initial burst
release over the first 3 days, CTGF was released at a steady rate of 0.08 ± 0.02 ng/day/cm suture during the subsequent 12 days (Fig. 1d). With a cumulative release of 5.9 ± 0.4 ng/cm suture over the full 15-day period and an
average suture length of 20 cm/repair (Table 1), it is anticipated that approximately 120 ng of CTGF would be
delivered to the repair center in vivo.

Site-specific delivery of ASCs and CTGF was achieved during tendon repair. A clinically relevant canine flexor tendon transection and repair model was used to evaluate the potential of ASCs and CTGF
for enhancing tendon healing17,18. As shown in Fig. 2, CTGF was delivered to the interior of repaired tendons
using the porous core sutures described above, and ASCs were applied to the repair surface via our previously
reported cell sheet approach10,11. The delivery of ASCs and growth factors was previously validated via tracking of
GFP-expressing ASCs10,11 and pre-labeled proteins in porous sutures15 in repaired tendons. The biocompatibility
of ASC sheet and porous suture was previously confirmed by cell viability assays in vitro10,15.
The overall impact of ASCs and CTGF on early tendon healing response. The overall healing
response was grossly compared among tendons from three repair groups (N = 10 per group): Control (repaired
with unloaded porous suture), CTGF (repaired with CTGF-loaded porous suture) and CTGF+ASC (repaired
with CTGF-loaded porous suture and ASC sheet) 14 days after flexor tendon repair. After sacrifice, repaired
tendons were surgically exposed and visually assessed. As detailed in Table 1, the control group had the worst outcomes, with one rupture, one 1.8 mm gap, and two repairs with apparent adhesions. In contrast, only one rupture
and one tendon with adhesions were noted in CTGF-treated tendons, and only one tendon with adhesions was
SCIENTIfIC Reports | (2018) 8:11078 | DOI:10.1038/s41598-018-29474-8
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Group

Control

CTGF

CTGF+ASC

Animal
#

Age
(year)

Weight
(Kg)

Digit

Tendon
usage

Adhesion

Gap
(mm)/Rupture

Core suture
length (cm)

1

3.1

26.3

1-2nd

RNA

yes

no

20.3

2

1.5

24.9

2-5th

RNA

no

1.8

20.9

3

3.3

22.7

3-2nd

RNA

no

no

19.9

4

1.7

24.9

4-5th

RNA

no

no

19.0

5

3.1

22.2

5-2nd

RNA

yes

no

20.5

6

2.0

24.0

6-5th

RNA

no

no

19.7

7

1.8

23.6

7-2nd

histology

no

no

20.8

8

2.9

20.4

8-5th

histology

no

no

21.0

9

1.7

20.4

9-2nd

histology

no

no

19.3

10

1.8

21.3

10-5th

excluded

n/a

rupture

19.9

11

2.6

25.9

11-2nd

RNA

no

no

22.3

12

2.5

24.0

12-5th

RNA

no

no

20.4

13

1.5

22.7

13-2nd

RNA

yes

no

21.0

14

2.0

22.7

14-5th

RNA

no

no

19.9

15

2.0

20.4

15-2nd

excluded

n/a

rupture

19.9

16

4.0

22.7

16-5th

histology

no

no

18.6

17

4.5

25.4

17-5th

RNA

no

no

20.7

18

1.5

23.1

18-2nd

RNA

no

no

20.5

19

2.1

22.7

19-2nd

histology

no

no

20.6

20

4.8

20.4

20-5th

histology

no

no

20.2

11

2.6

25.9

11-5th

RNA

no

no

20.0

12

2.5

24.0

12-2nd

RNA

no

no

20.3

13

1.5

22.7

13-5th

RNA

yes

no

21.5

14

2.0

22.7

14-2nd

RNA

no

no

20.4

15

2.0

20.4

15-5th

RNA

no

no

20.1

16

4.0

22.7

16-2nd

histology

no

no

20.6

17

4.5

25.4

17-2nd

RNA

no

no

20.1

18

1.5

23.1

18-5th

RNA

no

no

21.2

19

2.1

22.7

19-5th

histology

no

no

19.9

20

4.8

20.4

20-2nd

histology

no

no

20.2

Table 1. A summary of animals involved in the study.

Figure 2. Site-specific delivery of ASCs and CTGF during flexor tendon repair. (a) A schematic illustration of
CTGF and ASC delivery during flexor tendon repair. (b) A representative image of a hematoxylin and eosinstained cross section of an CTGF+ASC treated canine flexor digitorum profundus (FDP) tendon 14 days after
repair.
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Figure 3. The impact of CTGF/CTGF+ASC treatment on tendon inflammatory response. (a–f) Changes
in relative abundance of inflammation-related genes in flexor tendons 14 days after repair and indicated
treatments. *P < 0.05 between indicated groups by Dunn’s (b, c and d) or Student-Newman-Keuls post-hoc
tests (a); ^P < 0.05 compared to paired uninjured tendons by paired t-tests. (g and h) Representative images (g)
and quantification (h) of hematoxylin and eosin-stained coronal sections of zone 2 flexor digitorum profundus
tendons subjected to the indicated treatments. The sections are ~250 µm from the volar surface of the tendons.
The arrows indicate the regions where cells are accumulated at the tendon surface. The insets show enlarged
views of the boxed region within each image (blue scale bar = 20 μm). *P < 0.05 between indicated groups by
Student-Newman-Keuls post-hoc tests.

observed in CTGF and ASC co-treated tendons. As such, the percentage of overall postoperative complication
(adhesion plus gap/rupture) for Control, CTGF, and CTGF+ASC group were 40%, 20%, and 10%, respectively
(“N-1” Chi-squared test, P = 0.342 and 0.131 for CTGF and CTGF+ASC vs. Control, respectively), implicating a
potential positive effect of CTGF+ASC combined treatment in improving flexor tendon healing.

ASCs and CTGF modulate the inflammatory response during tendon healing. ASCs are known
to attenuate tendon inflammatory response by promoting macrophage polarization toward an alternative M2
phenotype and away from the default pro-inflammatory M1 phenotype10,11. CTGF, by enriching endogenous
CD146+ tendon progenitor/stem cells, may produce a similar effect13,21. To determine the inflammation-related
effects of ASCs and CTGF during tendon healing, gene expression levels were compared among repaired tendons
from Control (N = 6), CTGF (N = 6) and CTGF+ASC (N = 7) groups. Tendon injury substantially increased
the expression levels of pro-inflammatory genes IL1B, IL6 and IFNG in control tendons (Fig. 3a–c, paired t-test
compared to contralateral uninjured tendons, P = 0.034, 0.013 and 0.013, for Control, CTGF, and CTGF+ASC
groups, respectively). Treatment with CTGF, either applied alone or in combination with ASCs, significantly
reduced IL1B (Fig. 3a; one-way ANOVA, P = 0.016) and IL6 (Fig. 3b; one way-ANOVA, P = 0.002) expression
SCIENTIfIC Reports | (2018) 8:11078 | DOI:10.1038/s41598-018-29474-8
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Figure 4. The impact of CTGF/CTGF+ASC treatment on tendon cell growth and differentiation. (a–d)
Changes in relative abundance of genes involved in cell growth and differentiation in flexor tendons 14 days
after repair and indicated treatments. ^P < 0.05 compared to paired uninjured tendons by paired t-tests.

relative to control tendons, thus demonstrating anti-inflammatory effects of CTGF. CTGF alone and in combination with ASCs enhanced IL4 expression (Fig. 3d; one-way ANOVA, P = 0.039), a well-known M2 macrophage
stimulator22, further supporting positive effects of treatment on inflammation during tendon healing. However,
there were no significant differences when comparing CTGF to CTGF+ASC for the expression of most of the
inflammation-related genes investigated, with the exception of IFNG, which was decreased in the CTGF+ASC
group compared to control (Fig. 3c; one-way ANOVA, P = 0.014, Control vs. CTGF+ASC; P = 1.000, Control
vs. CTGF). IFNG encodes Interferon γ, which primes the pro-inflammatory M1 macrophage phenotype23; the
results therefore indicate an anti-inflammation function provided by ASCs. No apparent differences in IL10
(Fig. 3e; one-way ANOVA, P = 0.771) and IL13 (Fig. 3f; one-way ANOVA, P = 0.982) expression levels were
detected between repair groups. Nevertheless, IL10 was induced in all repaired tendons compared to paired uninjured tendons (Fig. 3e; paired t-test, P = 0.003, 0.001 and 0.000 for Control, CTGF, and CTGF+ASC, respectively). Furthermore, significant increases in IL13 expression levels were detected in tendons from CTGF and
CTGF+ASC but not Control groups compared to uninjured tendons (Fig. 3f; paired t-test, P = 0.138, 0.009 and
0.000 for Control, CTGF and CTGF+ASC, respectively).
At the tissue level, tendon samples from each repair group (N = 3 per group) were sectioned longitudinally
and stained with hematoxylin and eosin. As shown in Fig. 3g, tendon injury induced cell accumulation (in dark
blue) at the periphery of repaired tendons (arrows). Cell accumulation was more prominent in the control tendons than in the CTGF- or CTGF+ASC-treated tendons. A close examination and quantitative analysis of cellularity within these regions (insets in Fig. 3g,h) revealed distinct cell compositions between the control and
treated tendons: the control tendons were primarily occupied by round mononuclear and polymorphonuclear
cells (One-way ANOVA, P = 0.002); in contrast, more elongated fibroblast-like cells were present in CTGF- or
CTGF+ASC-treated tendons (One-way ANOVA, P = 0.002). Collectively, these findings strongly support the
gene expression results demonstrating anti-inflammatory effects of CTGF and CTGF+ASC during tendon
healing.

The effects of ASCs and CTGF on proliferation and tenogenesis during tendon healing.

The
impact of ASC and CTGF on cell growth and differentiation was assessed at the mRNA level for genes involved in
cell proliferation (CCND1, Fig. 4a) and fibroblast/tenocyte growth and differentiation (BFGF, TNMD and SCX,
Fig. 4b–d). Compared to paired uninjured tendons, while all repaired tendons exhibited lower levels of BFGF
(Fig. 4c; paired t-test, P < 0.001 for all three repair groups) and SCX (Fig. 4e; paired t-test, P = 0.023, 0.000 and
0.001 for Control, CTGF and CTGF+ASC group, respectively), only CTGF-treated tendons expressed a significantly higher than normal level of TNMD (Fig. 4d; paired t-test, P = 0.144 [Control], 0.014 [CTGF] and 0.050
[CTGF+ASC]), indicating a beneficial effect of CTGF treatment. No significant differences were detected when
comparing the three repair groups for any gene examined (one-way ANOVA: P = 0.611 [CCND1], 0.078 [BFGF],
0.137 [TNMD] and 0.284 [SCX]).
Previous reports have demonstrated induction of CD146+ stem cells by CTGF during tendon healing14,21.
We therefore determined MCAM (encoding CD146) expression levels in repaired tendons. Regardless of the
repair group, MCAM levels in repaired tendons were over two-fold greater than those in paired uninjured tendons (Fig. 5a; paired t-test, P = 0.075 [Control], 0.004 [CTGF] and 0.053 [CTGF+ASC]); however, no significant
effect by either CTGF or CTGF+ASC treatment was detected (One-way ANOVA, P = 0.206). At the tissue level,
CD146+ cells were detected via immunostaining on coronal sections of repaired tendons (N = 3 per group).
Among the three regions of interest — tendon surface, core suture and repair center (Fig. 5b) — CD146+ cells
(dark brown, arrows in Fig. 5c) mostly accumulated at the tendon surface away from the repair center (arrows in

SCIENTIfIC Reports | (2018) 8:11078 | DOI:10.1038/s41598-018-29474-8
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Figure 5. The impact of CTGF/CTGF+ASC treatment on CD146+ tendon progenitor/stem cell expression.
(a) Changes in relative abundance of CD146 gene MCAM in flexor tendons 14 days after repair and indicated
treatments. ^P < 0.05 compared to paired uninjured tendons by paired t-tests. (b) Annotated coronal section of
a repaired flexor tendon indicating locations of regions of interest. (c) Representative images and quantifications
of CD146 staining at the indicated regions of interest in flexor tendons from three repair groups. The sections
are ~250 µm from the volar surface of the tendons. *P < 0.05, by Student-Newman-Keuls post-hoc tests.

red boxes in Fig. 5b,c). CD146+ cells were also observed around the core suture (arrows in blue boxes in Fig. 5b,c)
distal to the repair center (arrows in black boxes in Fig. 5b,c). Comparing the three repair groups, more CD146+
cells were detected at the tendon surface in CTGF+ASC-treated tendons than in Control and CTGF-treated
tendons (One-way ANOVA, P = 0.003, Fig. 5c). A trending increase in CD146+ cells was also found in the region
along core suture tracks in CTGF+ASC-treated tendons (One-way ANOVA, P = 0.05; Fig. 5c). No apparent difference in CD146+ cells at the repair center was noted in tendons between any of the repair groups (One-way
ANOVA, P = 0.150; Fig. 5c).

ASCs and CTGF promote matrix regeneration during tendon healing. At the gene expression level,

COL1A1 was increased by ~20-fold in healing tendons compared to uninjured tendons (Fig. 6a; paired t-test,
P < 0.001 compared to paired uninjured tendons for all three groups). In contrast, COL2A1 expression in healing
tendons was reduced by over 50-fold compared to uninjured tendons (Fig. 6b; paired t-test, P = 0.019 [Control],
0.014 [CTGF] and <0.001 [CTGF+ASC]). The reduction in COL2A1 expression was attenuated following
either CTGF or CTGF+ASC treatment (one-way ANOVA, P = 0.005). Expression of COL3A1 and COL5A1 was
increased in healing tendons compared to uninjured tendons (Fig. 6c,d; paired t-test, P < 0.004 for all groups).
Treatment with CTGF alone led to increased expression of COL5A1 compared to control and CTGF+ASC groups
(one-way ANOVA, P = 0.002 among three repair groups). The addition of ASCs to CTGF-treated tendons lowered COL3A1 (encode type III collagen) level in repaired tendons (One-way ANOVA, P = 0.007 between CTGF
and CTGF+ASC group). As type III collagen has been linked to scar formation and inferior tendon mechanical
properties24, these results support a beneficial effect of the CTGF+ASC combined treatment.
With regard to matrix degrading enzymes, MMP1 expression levels in repaired control tendons were increased
by over 2000-fold compared to uninjured tendons (Fig. 6e; Signed Rank Test, P = 0.031). Likewise, MMP13 levels in control tendons were over 200-fold greater than those in paired uninjured tendons (Fig. 6f; paired t-test,
P = 0.006). Treatment either with CTGF or CTGF+ASC significantly attenuated the injury-induced MMP13
expression in repaired tendons (Fig. 6f; one-way ANOVA, P = 0.004 among three repair groups). Although
no significant change in MMP1 expression was detected following CTGF or CTGF+ASC treatment (Fig. 6e;
SCIENTIfIC Reports | (2018) 8:11078 | DOI:10.1038/s41598-018-29474-8
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Figure 6. The impact of CTGF/CTGF+ASC treatment on tendon matrix remodeling. (a–g) Changes in relative
abundance of genes associated with tendon matrix remodeling in flexor tendons 14 days after repair. *P < 0.05
between indicated groups by Dunn’s (b,f and g) or Student-Newman-Keuls post-hoc tests (c and d). ^P < 0.05
compared to paired uninjured tendons by paired t-tests. (h,i) Representative images (h) and semiquantitative
analysis (i) for new collagen synthesis in pentachrome-stained coronal sections of flexor tendons 14 days after
repair and indicated treatments. The sections are ~250 µm from the volar surface of the tendons. The arrows
point out the regions where newly formed collagens are present in treated tendons.

one-way ANOVA, P = 0.159), a trend toward reduced MMP1 expression was apparent in treated tendons. In
addition, MMP3 levels, which were not altered in untreated control tendons (Fig. 6g; paired t-test, P = 0.926 vs.
paired uninjured tendons), were reduced in tendons treated with either CTGF or CTGF+ASC (Fig. 6g; one-way
ANOVA, P = 0.009 among three repair groups). Collectively, gene expression analysis indicated that CTGF and
CTGF+ASC treatments enhanced the anabolic response while inhibiting the catabolic response associated with
tendon matrix remodeling.
At the tissue level, pentachrome staining was performed to assess tendon matrix remodeling in repaired tendons (N = 3 per group). Pentachrome staining is indicative of the stage of collagen maturation according to a
color scheme from green (immature) through red (mature) (Fig. 6h)25,26. Robust collagen production was seen
in repaired tendons, particularly following CTGF- or CTGF+ASC treatment (Fig. 6h). Semiquantitative analysis
confirmed that newly produced collagens occupied approximately 10% greater area in CTGF and CTGF+ASC
treated tendons than in control tendons (Fig. 6i; One-way ANOVA, P = 0.008 among three groups). Moreover,
the newly produced collagen was present in the tendon interior (black arrows in Fig. 6h) and largely in parallel to
the tracks of the core suture, supporting an effect of suture-delivered CTGF.

Discussion

After operative repair, tendon healing progresses through phases of inflammation, proliferation, and remodeling.
Each of these phases is a potential therapeutic target for enhanced healing. Previously, we demonstrated positive
effects from ASC administration on the early inflammatory phase of healing and positive effects from CTGF
application on the later proliferative phase of healing. These treatments were combined in the current study:
ASCs were delivered to the flexor tendon surface via cell sheets and CTGF was delivered to the tendon interior via
porous sutures. The approach was first validated by demonstrating the mechanical integrity and delivery capability of the porous sutures. Its efficacy was then demonstrated in a clinically relevant large animal model of flexor
tendon injury and repair. At the mRNA and tissue levels, CTGF+ASC treatment led to an attenuated tendon
inflammatory response and increased tendon matrix regeneration, thus providing a promising new treatment
strategy for flexor tendon repair.
CTGF was introduced into this study due to its potential to promote tendon regeneration13,14. Interestingly,
in addition to enhancing TNMD expression and tendon matrix synthesis, CTGF was found to attenuate tendon
inflammation, leading to reduced IL1B and IL6 expression and inflammatory cell infiltration during flexor tendon
healing. As the effect was accompanied by an increased expression of a M2 stimulator gene IL4 and a switch of
primary infiltrated cells from inflammatory mononuclear cells to fibroblast-like cells, CTGF might be involved
SCIENTIfIC Reports | (2018) 8:11078 | DOI:10.1038/s41598-018-29474-8
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in modulating macrophage polarization. This concept is consistent with a recent report showing CTGF can suppress iNOS+ M1 macrophages via enrichment of CD146+ tendon stem/progenitor cells21. However, when assessing the expression level of the CD146 gene, MCAM, and the immunohistochemical pattern of CD146+ cells in
repaired tendons, we found no apparent differences between CTGF-treated and untreated control tendons. This
discrepancy may be due to the 14-day time point studied, as the presence of CTGF-enriched CD146+ cells typically occurs early in tendon healing. Specifically, these cells have been shown to peak within the first week after
CTGF delivery and are barely detectable by two weeks14. Moreover, as CD146+ cells account for less than 1% of
all cells in uninjured tendon14, the effect of CTGF might also be limited by a lack of endogenous stem cells within
flexor tendon. In line with this premise, the current study demonstrates an enrichment of CD146+ cells in the
CTGF-repaired tendons within the treatment group that included ASCs. Alternatively, other mechanisms may
contribute to the anti-inflammation function of CTGF. A follow-up short-term study (e.g., 7 days after repair)
would be helpful to assess the potential causal link between CD146+ cells and CTGF function and to decipher the
underlying mechanism by which CTGF modulates inflammation during flexor tendon healing.
As expected, the combined application of ASCs and CTGF was more effective than CTGF treatment alone
in regulating tendon inflammation and regeneration. In accord with the roles of ASCs in modulating tendon
inflammation and promoting CD146+ tendon stem or progenitor cells after tendon repair10,11, the combined
treatment reduced the expression of IL1B, IL6, IFNG (inducing inflammatory M1 macrophage phenotype), and
COL3A1 (associated with scarring) and simultaneously increased CD146+ cells in repaired tendons. Accordingly,
the combined treatment led to improved collagen production and a trending reduction of postoperative complications. Future studies should evaluate an ASC-alone treatment group and determine macrophage polarization
due to ASC, CTGF or CTGF+ASC treatment. These studies may further differentiate the roles and mechanisms
of ASCs, CTGF and CTGF+ASC in modulating tendon inflammation and healing responses.
A limitation of this study was the examination of only one time-point of healing. In addition to assessing the
short-term effect, as discussed above, analysis of longer healing time-points are also necessary to determine if
the early changes observed here will lead to improved biomechanical outcomes. Nevertheless, this study demonstrates the feasibility of cell sheets and porous suture as vehicles for the site-specific delivery of cells and growth
factors in flexor tendon repair. Furthermore, the results support the use of ASCs and CTGF as a combined strategy for enhancing flexor tendon healing and is worthy of further investigation.

Methods

Study Design.

With the approval from Washington University Institutional Animal Care and Use
Committee, 10 adult female canines were included in this study. All experiments were performed in accordance
with relevant guidelines and regulations. As detailed in Table 1, with a paired design, zone 2 flexor digitorum
profundus tendon (FDP) transections and repairs were conducted in the 2nd and 5th digits of the right front paw
of each animal. Specifically, FDP tendons were transected at the level of the proximal interphalangeal joint and
repaired using an 8-strand Winters-Gelberman core suture technique27. The repaired tendons were assigned to
two treatment groups: CTGF and CTGF+ASC (N = 10/group). In the CTGF group, the repaired digits were
treated with porous suture loaded with CTGF. In the CTGF+ASC group, in addition to CTGF, the repaired tendons were further treated with a thin cell sheet containing autologous ASCs10. In order to minimize animal usage,
flexor tendons from a separate study16 (N = 10) were repaired in the same manner as those from the CTGF and
CTGF+ASC groups with porous suture and without CTGF and used as control. The corresponding left (non-operated) digital flexor tendons served as uninjured controls (Uninjured group). With 10 tendon samples from each
group, 7 samples were designated for RNA isolation and subsequent tendon gene expression analysis, and the
remaining 3 samples were assigned for histological assessments. All repaired limbs were immobilized after surgery using fiberglass shoulder spica casts with the elbows flexed to 90° and the wrists flexed to 70° and subjected
to controlled passive mobilization as detailed previously9.

Generation and characterization of CTGF-loaded porous sutures. 4-0 Supramid sutures (S. Jackson,
Alexandria, VA) were pre-treated with a swelling and freeze-drying technique to create porous at the outer
layer of the suture15. The porosity of sutures was determined by scanning electron microscopy and analyzed via
MATLAB software using a custom-made code. Uniaxial tensile testing was performed to compare material properties between porous and unmodified sutures (N = 7–8/group) as previously described16.
Recombinant human CTGF (BioVendor, Asheville, NC) was loaded into porous sutures via a heparin/fibrin
delivery system (HBDS)19,20. In brief, dry sterile sutures were first incubated in a loading solution containing
58.8 µM plasminogen-depleted human fibrinogen (EMD Millipore, Burlington, MA), 423 µM bi-domain HBDS
peptide (GenScript, Piscataway, NJ), 106 µM heparin (Sigma Aldrich, St. Louis, MO) and 30 µg/ml CTGF in TBS/
BSA (50 mM Tris [pH 7.4], 150 mM NaCl and 0.1% w/v BSA) at 4 °C overnight. The loaded sutures were then
incubated in a thrombin solution containing 20 U/ml thrombin (Sigma Aldrich), 13.7 mM CaCl2 and 30 µg/ml
CTGF in TBS/BSA at 37 °C for 2 hours. CTGF release from loaded porous sutures (N = 3) was determined in
TBS/BSA solution at 37 °C. The solution was replaced with fresh TBS/BSA daily in the first three days after loading and then every other day until 15 days after loading. CTGF contents in the replaced TBS/BSA solutions were
determined with a human CTGF ELISA kit (Bio Ocean, Shoreview, MN) using a protein standard generated with
the CTGF from BioVendor.
In vivo delivery of ASC sheets. Two weeks prior to tendon repair, autologous ASCs were isolated from
subcutaneous fat tissues and expanded in culture as described previously10,11. Passage 3 ASCs were subsequently
cultured on the collagen sheet at a density of 16,000 cells/cm2 for 3–4 days in vitro and then applied in vivo following suture repair as illustrated in Fig. 2a.
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Gene symbol

Gene name

Assay number

Accession number

Amplicon
length (bp)

BFGF

basic fibroblast growth factor

Cf03460065_g1

XM_003432481.3

147

CCND1

cyclin D1

Cf02626707_m1

NM_001005757.1

85

COL1A1

collagen, type I, alpha 1

Cf02623126_m1

NM_001003090.1

87

COL2A1

collagen, type II, alpha 1

Cf02622836_m1

NM_001006951.1

72

COL3A1

collagen, type III, alpha 1

Cf02631370_m1

XM_845916.4

78

COL5A1

collagen, type V, alpha 1

Cf02645008_m1

XM_014116870.1

77

GAPDH

glyceraldehyde-3-phosphate dehydrogenase

Cf04419463_gH

NM_001003142.2

54

IFNG

interferon, gamma

Cf02623316_m1

NM_001003174.1

117

IL1B

interleukin 1, beta

Cf02671953_g1

NM_001037971.1

78

IL4

interleukin 4

Cf02623112_m1

NM_001003159.1

97

IL6

interleukin 6

Cf02624152_g1

NM_001003301.1

80

IL10

interleukin 10

Cf02624265_m1

XM_001003077.1

89

IL13

interleukin 13

Cf02624081_m1

NM_001003384.1

95

MCAM

melanoma cell adhesion molecule/CD146

Cf02651439_m1

XM_014113367.1

64

MMP1

matrix metallopeptidase 1

Cf02651000_g1

XM_546546.5

63

MMP3

matrix metallopeptidase 3

Cf02625960_m1

NM_001002967.1

79

MMP13

matrix metallopeptidase 13

Cf02623587_m1

XM_536598.4

78

PPIB

peptidylprolyl isomerase B (cyclophilin B)

Cf02629556_m1

XM_847296.4

78

TNMD

Tenomodulin

Cf02665570_m1

XM_538101.4

106

Table 2. Commercial Taqman primers and probes used in the study.

Gene expression analysis. Fourteen days after repair, tendon fragments flanking the repair site (approximately 10 mm from each side of the transection line) were dissected and subjected to total RNA isolation, cDNA
synthesis, and quantitative TaqMan RT-PCR as described previously10,11. All TaqMan primers and probes used in
this study were purchased from Applied Biosystems TaqMan Gene Expression Assays (Woolston, UK; Table 2)
except for SCX, which was custom designed (gene name, scleraxis; accession number, XM_005628297; forward
primer, 5′-gca agc tct cca aga tcg ag-3′; reverse primer, 5′-ctt tct ctg gtt gct gag gc-3′; probe, 5′-gtc cag cta cat ctc
gca cc-3′). GAPDH and PPIB were used as endogenous reference genes. The relative abundances of target genes in
each sample were determined with ∆∆Ct method and expressed as fold changes of respective uninjured controls.
Tendon histology and immunohistochemistry. Serial coronal paraffin sections (5 µm thick) were prepared from flexor tendons as previously described10,11. After deparaffinization, sections were either subjected to
hematoxylin and eosin or pentachrome staining (American MasterTech, Lodi, CA)25,26 to examine the overall
healing response and collagen regeneration, respectively. The cellularity at the tendon surface was determined
by counting the number of fibroblast-like cells, polymorphonuclear cells, and mononuclear cells on hematoxylin and eosin-stained slides at a magnification of 40 at the predefined region indicated in Fig. 5b. The results
are shown as the percentage of total cell counts for each cell type. The amount of new collagen formation was
assessed by determining tissue area and mature collagen area (in red) in pentachrome stained sections using
Adobe Photoshop 12.1 (Adobe Systems Incorporated) and expressed as a percentage of new collagen area in the
entire tendon section: (tissue area - mature collagen area)/tissue area × 100%. For CD146 immunohistochemistry, after heat-induced antigen retrieval, sections were incubated with rabbit anti-CD146 antibodies (Abcam,
Cambridge, UK; #Ab75769, 1:200 dilution) at 4 °C overnight. After three washes with 0.05% Triton X-100 in PBS
(PBST), the sections were further incubated with biotinylated anti-rabbit IgG (Sigma Aldrich; 1:400 dilution)
at room temperature for 1 hour, followed by ExtrAvidin-Peroxidase (Sigma Aldrich; 1:100 dilution) for 30 min.
After three washes with PBST, the sections were developed with a DAB-Plus Substrate Kit (Life Technologies,
Carlsbad, CA) and then counterstained with Mayer’s hematoxylin. CD146+ cells at the regions of tendon surface,
core suture, and repair center (Fig. 5b) were counted and the results were normalized by the lengths of tendon
surface, core suture, and transection line, respectively on coronal sections of repaired tendons covering a region
approximately 10 mm from each side of the transection line.
Statistics.

Unless described elsewhere, all data are shown as mean + standard deviation; a one-way analysis
of variance (ANOVA) followed by Student-Newman-Keuls or Dunn’s post-hoc test (when appropriate) was performed to compare gene expression among groups; two-tailed paired Student’s t-tests were used to compare gene
expression levels in repaired and contralateral uninjured tendons; a “N−1” Chi-squared test was employed to
compare the percentage of postoperative complications between treated and control groups28,29. The significance
level was set at P < 0.05.
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